Moderna to Sell Additional 176.5 Million Covid-19 Vaccine Doses to Covax for Lower-Income Countries
October 12 2021 - 10:06AM
Dow Jones News
By Robb M. Stewart
Biotechnology company Moderna Inc. will sell an additional 176.5
million doses of its Covid-19 vaccine to Covax, the world's main
effort to supply such vaccines to poorer nations.
Gavi, the Vaccine Alliance exercised an option for the doses for
the Covax facility to supply low-income countries, Moderna said
Tuesday. All the doses are being sold at the lowest tiered price,
with 116.5 million doses expected to be delivered in the first
three months of next year and 60 million in the second quarter, the
company said.
Covax, a facility started last year by the World Health
Organizaton, retains an option to buy 116.5 million doses for
delivery in the third quarter of 2022 and a further 116.5 million
doses for delivery the following quarter. That is in addition to
the 34 million doses bought for delivery in the fourth quarter of
this year.
Moderna said the 210 million doses purchased to date by Covax
are 100 micrograms per dose. The company recently requested
authorization of a 50 ug dose as a booster from the same vial,
which it said would significantly increase the number of usable
doses procured by Covax at no additional cost. The average purchase
price across all doses purchased to date is just under $10 per 100
ug dose, it said.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
October 12, 2021 09:51 ET (13:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024
